Physician profile
Maureen Mcgeehan
NPI 1245255363
$4,969.07
in general payments reported to CMS, 2019-2025
22 companies · $911 in 2025
The $911 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $380 · 2021: $503 · 2022: $874 · 2023: $915 · 2024: $776 · 2025: $911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,350 · Education: $253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,350.07 |
| Education | $252.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,025.31 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $926.44 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $802.38 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $418.96 | 2019-2025 | |
| Genzyme Corporation | $377.23 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $194.90 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $166.97 | 2020-2023 | Cuvitru, Takhzyro |
| Genentech USA, INC. | $148.55 | 2019-2024 | Xolair |
| Alk-Abello, INC | $142.68 | 2022-2023 | Grastek, Ragwitek, Odactra |
| Amgen INC. | $135.54 | 2021-2025 | Tezspire |
| Blueprint Medicines Corporation | $121.86 | 2025 | Ayvakit |
| Optinose US, INC. | $97.82 | 2019-2023 | |
| Grifols USA, LLC | $83.19 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $70.12 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.47 | 2020-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $48.33 | 2022-2023 | |
| Hospira, INC. | $45.47 | 2024-2025 | |
| Octapharma USA, INC. | $29.86 | 2022 | |
| Lilly USA, LLC | $21.14 | 2025 | Ebglyss |
| Merck Sharp & Dohme LLC | $18.77 | 2021 | |
| Shire North American Group INC | $17.49 | 2019 | |
| Covis Pharma Gmbh | $13.59 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maureen Mcgeehan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.